Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health.

Lipozem is a natural supplement specifically made to offer weight loss benefits to those struggling with stubborn body weight ...

Mitolyn is a Harvard-research-based optimal weight loss aid that claims to support metabolism naturally. The creators of this ...

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

These amendments represent the first significant changes to “healthy” labeling requirements in 30 years. In its new scheme, ...

The Food and Drug Administration (FDA) recently issued a Notice announcing the availability of an updated final guidance for the industry ...

On January 6, the FDA announced the availability of draft guidance on accelerated approval for drugs and biological products, and consideration ...

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...